Brief: Hutchmed (China) Says NDA For Fanregratinib Accepted With Priority Review In China
29/12/2025 10:29
Dec 29 (Reuters) - HUTCHMED (China) Ltd 0013.HK: NDA FOR FANREGRATINIB ACCEPTED WITH PRIORITY REVIEW IN CHINA Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsKras: EGFR-Antibody licensing deal with GSK closes
Brief: Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals